ライフサイエンスコーパス: refractory anemia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ents in hemodialysis patients with treatment-refractory anemia.

2 event a downward spiral of iron toxicity and refractory anemia.

3 wing French-American-British classification: refractory anemia (20), refractory anemia with excess bl

4 Diagnoses included refractory anemia (7), refractory anemia with ringed sid

5 Patients presenting with refractory anemia and leukopenia with or without associa

6 y is an under-recognized cause of reversible refractory anemia and leukopenia, particularly neutropen

7 Severe, often refractory anemia is characteristic of the myelodysplast

8 distinct subtype of myelodysplastic syndrome-refractory anemia (MDS-RA).

9 d apoptotic/sub-G1 DNA content in early (ie. refractory anemia) MDS patients compared with normal ind

10 pitulates many features of early stage human refractory anemia/myelodysplastic syndrome, including in

11 n = 1; 5q- syndrome, n = 1; RCMD-RS, n = 1; refractory anemia, n = 1; refractory cytopenia with mult

12 We also discuss the management of refractory anemias other than TM that may require multip

13 quencies were significantly increased in MDS refractory anemia (RA) (P =.036 and P =.01, respectively

14 Patients with JMML and refractory anemia (RA) or RA-excess blasts (RAEB) exhibi

15 ophosphamide (120 mg/kg) in 30 patients with refractory anemia (RA) undergoing related (n = 17) or un

16 ritish (FAB) classification, 13 patients had refractory anemia (RA), 19 had RA with excess blasts (RA

17 n and 8 women (median age, 67 years), 20 had refractory anemia (RA), 3 had RA with ringed sideroblast

18 Among responders, 9 had refractory anemia (RA); 5 had RA with ringed sideroblast

19 We treated 8 anemic MDS patients (refractory anemia [RA] and refractory anemia with excess

20 re French-American-British (FAB) lower risk (refractory anemia [RA]/RA with ringed sideroblasts/chron

21 from 5 separate MDS aspirates were studied: refractory anemia, refractory anemia with ringed siderob

22 rom patients with low-grade/early-stage MDS (refractory anemia/refractory anemia with ring sideroblas

23 s with beta-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions

24 with large hepatic adenomas had severe iron refractory anemia similar to that observed in anemia of

25 ally similar to those found in patients with refractory anemia, suggesting that, in some cases, the m

26 tish classification: refractory anemia (20), refractory anemia with excess blasts (35), refractory an

27 Sixty percent had refractory anemia with excess blasts (n = 136) or with e

28 ractory anemia with ringed sideroblasts (5), refractory anemia with excess blasts (RAEB) (4), and RAE

29 ced complementary DNA from bone marrow of 47 refractory anemia with excess blasts (RAEB) patients, 29

30 However, in the high-risk refractory anemia with excess blasts (RAEB) stages of MD

31 Following WHO recommendations, refractory anemia with excess blasts (RAEB)-2 diagnosis

32 vival durations were longer in patients with refractory anemia with excess blasts (RAEB).

33 excess blasts in transformation (RAEB-t), or refractory anemia with excess blasts (RAEB).

34 mic MDS patients (refractory anemia [RA] and refractory anemia with excess blasts [RAEB-1]) with ATG

35 or high-risk myelodysplastic syndrome (MDS) (refractory anemia with excess blasts [RAEB] or RAEB-t, 6

36 179 of 1505 loci after blast transformation (refractory anemia with excess blasts [RAEB]/AML).

37 Responders included two patients with refractory anemia with excess blasts and one patient wit

38 diagnosis, the FAB distinctions between MDS (refractory anemia with excess blasts and refractory anem

39 rthermore, we demonstrate that patients with refractory anemia with excess blasts in transformation (

40 lasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (

41 ewly diagnosed acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (

42 ory anemia with ringed sideroblasts (9), and refractory anemia with excess blasts in transformation (

43 ewly diagnosed acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (

44 In current medical practice, patients with refractory anemia with excess blasts in transformation (

45 While in advanced MDS (refractory anemia with excess blasts in transformation [

46 DS (refractory anemia with excess blasts and refractory anemia with excess blasts in transformation)

47 emia with excess blasts and one patient with refractory anemia with excess blasts in transformation.

48 refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia

49 th multilineage dysplasia (RCMD)-RS, 11 with refractory anemia with excess blasts-1 (RAEB1)-RS, and 5

50 ts (RCMD-RS) and UPD4q24, and five patients (refractory anemia with excess blasts-II, n = 1; 5q- synd

51 =.036 and P =.01, respectively) but not MDS refractory anemia with excess blasts.

52 X1 have been identified in 15% to 40% of MDS-refractory anemia with excess of blasts (RAEB) and MDS/A

53 the 533 patients with newly diagnosed AML or refractory anemia with excess of blasts (RAEB) entering

54 y anemia with ringed sideroblasts (RARS) and refractory anemia with multilineage dysplasia and ringed

55 factor 3b subunit 1 is mutated in 60%-80% of refractory anemia with ring sideroblasts (RARS) and RARS

56 Refractory anemia with ring sideroblasts (RARS) is a mye

57 More than 80% of patients with the refractory anemia with ring sideroblasts subtype of myel

58 e the association of the SF3B1 mutation with refractory anemia with ring sideroblasts, TET2/SRSF2 com

59 d < 5% blasts is required for a diagnosis of refractory anemia with ring sideroblasts.

60 Diagnoses included refractory anemia (7), refractory anemia with ringed sideroblasts (5), refracto

61 , refractory anemia with excess blasts (35), refractory anemia with ringed sideroblasts (9), and refr

62 response rate differed significantly between refractory anemia with ringed sideroblasts (RARS) and re

63 istent with the provisional MDS/MPD-U entity refractory anemia with ringed sideroblasts and thrombocy

64 S aspirates were studied: refractory anemia, refractory anemia with ringed sideroblasts, refractory a

65 itiation of erythropoietin (EPO) therapy for refractory anemia with ringed sideroblasts.

66 107 patients with MDS-RS, including 48 with refractory anemia with RS (RARS), 43 with refractory cyt

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。